AQEMIA

Aqemia is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases. What sets us apart is our unique quantum and statistical mechanics algorithms fuelling a generative AI to design novel drug candidates. The disruptive speed and accuracy of our technology platform allows us to scale drug discovery projects as technology projects.

AQEMIA headquartered in Europe, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Life Science, Pharmaceutical, Generative AI sector. The company focuses on Biotechnology and has secured $6.2B in funding across 96 round(s). With a team of 51-100 employees, AQEMIA is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - AQEMIA, raised $32.5M. Discover more about their projects, partnerships, and impact on our platform.